Outlook Therapeutics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q32026 FY2026 | $-0.09 | $-0.09 | +0.0% | Beat |
| Q22026 FY2026 | $-0.12 | $-0.16 | -33.3% | Miss |
| Q12026 FY2026 | $-0.17 | — | — | Miss |
Back to OTLK overview · OTLK holders · OTLK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.